Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2016

01.02.2016 | Breast Oncology

Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis

verfasst von: Francisco Igor B. Macedo, MD, Joseph J. Eid, MD, Jeff Flynn, PhD, Michael J. Jacobs, MD, Vijay K. Mittal, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Occult breast cancer (OBC) represents a rare clinical entity and poses a therapeutic dilemma. Due to limited experience, no optimal treatment approaches have yet been established.

Methods

A meta-analysis was performed using MEDLINE and EMBASE databases to identify all studies investigating the surgical options for OBC: (1) axillary lymph node dissection (ALND) with radiotherapy (XRT); (2) ALND with mastectomy; and (3) ALND alone. Comparative studies including nonoperative management (observation or XRT alone) were excluded. The primary endpoints were locoregional recurrence, distant metastasis, and mortality rates.

Results

The literature search yielded 42 publications. Seven studies met the inclusion criteria comprising 241 patients. Among these patients, 94 (39 %) underwent ALND with XRT, 112 (46.5 %) underwent mastectomy, and 35 (14.5 %) underwent ALND alone. Mean follow-up was 61.8 ± 16.2 months (range 5–396 months). Locoregional recurrence (12.7 vs. 9.8 %), distant metastasis (7.2 vs. 12.7 %), and mortality rates (9.5 vs. 17.9 %) were similar between ALND with XRT and mastectomy. ALND with XRT was superior to ALND alone regarding locoregional recurrence (12.7 vs. 34.3 %, p < 0.01) and there was a trend toward improved mortality rates (9.5 vs. 31.4 %, p = 0.09).

Conclusions

There was no difference in survival outcomes between mastectomy and ALND with XRT of patients with OBC. Radiotherapy improves locoregional recurrence and, possibly mortality rates of patients undergoing ALND. Based on this meta-analysis, combined ALND and radiation therapy may appear as the optimal surgical approach in these patients.
Literatur
1.
Zurück zum Zitat Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125:210–14.CrossRefPubMed Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125:210–14.CrossRefPubMed
2.
Zurück zum Zitat Kemeny MM, Rivera DE, Terz JJ, et al. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152:43–7.CrossRefPubMed Kemeny MM, Rivera DE, Terz JJ, et al. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152:43–7.CrossRefPubMed
3.
Zurück zum Zitat Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol. 1990;21:518–23.CrossRefPubMed Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol. 1990;21:518–23.CrossRefPubMed
4.
Zurück zum Zitat Patel J, Nemoto T, Rosner D. Axillary lymph node metastasis from an occult breast cancer. Cancer. 1981;47(12):2923–7.CrossRefPubMed Patel J, Nemoto T, Rosner D. Axillary lymph node metastasis from an occult breast cancer. Cancer. 1981;47(12):2923–7.CrossRefPubMed
5.
Zurück zum Zitat Montagna E, Bagnardi V, Rotmenez N, et al. Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat. 2011;129:867-75.CrossRefPubMed Montagna E, Bagnardi V, Rotmenez N, et al. Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Res Treat. 2011;129:867-75.CrossRefPubMed
6.
Zurück zum Zitat Blanchard DK, Farley DR. Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg. 2004;28:535–9.CrossRefPubMed Blanchard DK, Farley DR. Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg. 2004;28:535–9.CrossRefPubMed
7.
Zurück zum Zitat Jackson B, Scott‐Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg. 1995;61:431–4.PubMed Jackson B, Scott‐Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg. 1995;61:431–4.PubMed
8.
Zurück zum Zitat Svastics E, Ronay P, Bodo M. Occult breast cancer presenting with axillary metastasis. Eur J Surg Oncol. 1993;19:575–80.PubMed Svastics E, Ronay P, Bodo M. Occult breast cancer presenting with axillary metastasis. Eur J Surg Oncol. 1993;19:575–80.PubMed
10.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the Prisma Statement. Plos Med. 2009;6:1–6.CrossRef Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the Prisma Statement. Plos Med. 2009;6:1–6.CrossRef
11.
Zurück zum Zitat Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47(1):143–7.CrossRefPubMed Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47(1):143–7.CrossRefPubMed
12.
Zurück zum Zitat Rueth NM, Black DM, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22:90–5.CrossRefPubMed Rueth NM, Black DM, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22:90–5.CrossRefPubMed
13.
Zurück zum Zitat Varadarajan R, Edge SB, Yu J, et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology. 2006;71:456–9.CrossRefPubMed Varadarajan R, Edge SB, Yu J, et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology. 2006;71:456–9.CrossRefPubMed
14.
Zurück zum Zitat Woo SM, Son BH, Lee JW, et al. Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience. J Breast Cancer. 2013;16(4):410–6.CrossRefPubMedPubMedCentral Woo SM, Son BH, Lee JW, et al. Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience. J Breast Cancer. 2013;16(4):410–6.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Vlastos G, Jean ME, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2000;8(5):425–31.CrossRef Vlastos G, Jean ME, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2000;8(5):425–31.CrossRef
16.
Zurück zum Zitat He M, Tang LC, Yu KD, et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. EJSO. 2012;38:1022–8.CrossRefPubMed He M, Tang LC, Yu KD, et al. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. EJSO. 2012;38:1022–8.CrossRefPubMed
17.
Zurück zum Zitat Morris EA, Schwartz LH, Dershaw DD, et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205:437–40.CrossRefPubMed Morris EA, Schwartz LH, Dershaw DD, et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205:437–40.CrossRefPubMed
18.
Zurück zum Zitat Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in a patient with axillary node metastases and unknown primary malignancy. Radiology. 1999;212:543–9.CrossRefPubMed Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in a patient with axillary node metastases and unknown primary malignancy. Radiology. 1999;212:543–9.CrossRefPubMed
19.
Zurück zum Zitat De Bresser J, De Vos B, van der Ent F, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. EJSO. 2010;36:114–9.CrossRefPubMed De Bresser J, De Vos B, van der Ent F, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. EJSO. 2010;36:114–9.CrossRefPubMed
20.
Zurück zum Zitat Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. J Am Surg. 2005;190:609–13.CrossRef Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. J Am Surg. 2005;190:609–13.CrossRef
21.
Zurück zum Zitat Barton SR, Smith IE, Kirby AM, et al. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer. 2011;47(14):2099–106.CrossRefPubMed Barton SR, Smith IE, Kirby AM, et al. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer. 2011;47(14):2099–106.CrossRefPubMed
22.
Zurück zum Zitat van Ooijen B, Botenbal M, Henzen-Logmans SC. Axillary nodal metastases from an occult primary consistent with breast carcinomas. Br J Surg. 1993;80:1299–300.CrossRefPubMed van Ooijen B, Botenbal M, Henzen-Logmans SC. Axillary nodal metastases from an occult primary consistent with breast carcinomas. Br J Surg. 1993;80:1299–300.CrossRefPubMed
23.
Zurück zum Zitat Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000–6.CrossRefPubMedPubMedCentral Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000–6.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Trench DW, Page DL. The unknown primary presenting with axillary lymphadenopathy. In: Bland KI, Copeland EM, eds. The breast: comprehensive management of benign and malignant diseases, vol 2. 2nd edn. Philadelphia: W.B. Saunders, 1998:1447–52. Trench DW, Page DL. The unknown primary presenting with axillary lymphadenopathy. In: Bland KI, Copeland EM, eds. The breast: comprehensive management of benign and malignant diseases, vol 2. 2nd edn. Philadelphia: W.B. Saunders, 1998:1447–52.
25.
Zurück zum Zitat Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat. 2010;119:1–11.CrossRefPubMed Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat. 2010;119:1–11.CrossRefPubMed
26.
Zurück zum Zitat Campana F, Fourquet A, Ashby MA, et al. Presentation of axillary lymphadenopathy without detectable breast primary (T0N1b breast cancer): experience at Institut Curie. Radiother Oncol. 1989;15(4):321–5.CrossRefPubMed Campana F, Fourquet A, Ashby MA, et al. Presentation of axillary lymphadenopathy without detectable breast primary (T0N1b breast cancer): experience at Institut Curie. Radiother Oncol. 1989;15(4):321–5.CrossRefPubMed
27.
Zurück zum Zitat Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66(7):1461–7.CrossRefPubMed Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66(7):1461–7.CrossRefPubMed
28.
Zurück zum Zitat Shannon C, Walsh G, Sapunar F, et al. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11(5):414–8.CrossRefPubMed Shannon C, Walsh G, Sapunar F, et al. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11(5):414–8.CrossRefPubMed
Metadaten
Titel
Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis
verfasst von
Francisco Igor B. Macedo, MD
Joseph J. Eid, MD
Jeff Flynn, PhD
Michael J. Jacobs, MD
Vijay K. Mittal, MD
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2016
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5104-8

Weitere Artikel der Ausgabe 6/2016

Annals of Surgical Oncology 6/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.